Allovir Inc reports results for the quarter ended in December - Earnings Summary

Kalaris Therapeutics

10/02/2022 14:35

* Allovir Inc  ALVR.OQ  reported a quarterly adjusted loss
of 91
cents​​ per share for the quarter ended in December. The mean
expectation of four analysts for the quarter was for a loss
of 81 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Allovir Inc's reported EPS for the quarter was a loss
of 92
cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Allovir Inc shares had fallen by 33.8% this quarter.
    * The company reported a quarterly loss of $57.94 million.
    * Wall Street's median 12-month price target for Allovir Inc
is
$34.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated February 10 at 02:34 p.m.
 ​All figures in US dollars unless otherwise stated